Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
ImmVira Pharma Co. Ltd
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05602792CT.gov A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| t3011 (this asset) | ImmVira Pharma Co. Ltd | P1/2 | CC · 47 |
| 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER | University of Alabama at Birmingham | P4 | BB |
| Pembrolizumab | Essen Biotech | P2 | BB |
| Multiple Vitamins Injection | Women's College Hospital | P3 | BB |
| Trametinib | Cancer Research UK | P2/3 | B |
| Dabrafenib | Cancer Research UK | P2/3 | B |
| Nivolumab | H. Lee Moffitt Cancer Center and Research Institute | P2 | B |
| Binimetinib | H. Lee Moffitt Cancer Center and Research Institute | P2 | B |
| Mart-1 Antigen | National Institutes of Health Clinical Center (CC) | P2 | B |
+42 more in the Skin Carcinoma cohort
Other indications for t3011
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Melanoma | — | P2 | CCC · 52 |
| Colorectal Cancer | — | P1/2 | CCC · 50 |
| Esophageal Cancer | — | P1/2 | CC · 45 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- 1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMERUniversity of Alabama at BirminghamBB
- PembrolizumabEssen BiotechBB
- Multiple Vitamins InjectionWomen's College HospitalBB
- TrametinibCancer Research UKB
- DabrafenibCancer Research UKB
Citation
Floatz Terminal. t3011 in Skin Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/t3011-skin-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →